BD-AcAc2
Based on 1 Customer Validation
BD-AcAc2 (R,S-1,3-Butanediol acetoacetate diester) is an orally active, CNS-penetrant antiepileptic agent. BD-AcAc2 inhibits NF-κB, NLRP3 inflammasome, caspase-1/3, pyroptosis, apoptosis, and enhances autophagy. BD-AcAc2 exhibits antioxidant activity by modulating ROS, MDA, SOD, and GSH levels, and alleviates oxidative stress. BD-AcAc2 mitigates chronic colitis, counteracts Dextran Sodium Sulfate (DSS)-induced pathology, protects against central nervous system oxygen toxicity and acute lung injury, and exhibits anti-seizure efficacy. BD-AcAc2 can be used for the research of colitis, sarcopenia, acute lung injury, seizure, and obesity.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 58213-75-5
- Formula: C12H18O6
- Molecular Weight:258.27
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
|
NLRP3 inflammasome |
BD-AcAc2 (4% w/w; p.o.; 24 days) induces nutritional ketosis in healthy rats without altering normal colonic structure[1].
BD-AcAc2 (25% of dietary kcals; dietary; 9 weeks) prevents age-related increases in fat mass in mice[2].
BD-AcAc2 (2.5-10 g/kg; p.o.; single dose) protects mice from central nervous system oxygen toxicity and concomitant acute lung injury in a dose-dependent manner[3].
BD-AcAc2 (4 g/kg; i.g.; single dose) significantly increases blood βHB levels and raises the PTZ seizure threshold in rats[4].
BD-AcAc2 (30% of dietary energy; p.o.; 12 weeks) reduces body weight and adiposity in HFD-induced obese mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 7 weeks old, 180-200 g, chronic ulcerative colitis induced by 2% DSS for 7 days, followed by 1% DSS for 10 days, then 2% DSS for 7 days)[1]
-
Dosage:4% w/w
-
Administration:p.o.; ad libitum; 24 days
-
Result:Increased plasma β-hydroxybutyrate levels, achieving nutritional ketosis.
Significantly reduced the percentage of body weight loss compared to DSS-only rats.
Significantly decreased the colon weight-to-length ratio compared to DSS-only rats.
Significantly reduced the disease activity index and macroscopic damage index compared to DSS-only rats.
Increased survival rate compared to DSS-only rats.
Significantly lowered the colonic inflammation score compared to DSS-only rats.
Significantly suppressed DSS-induced increases in ROS and MDA levels, and significantly reversed DSS-induced decreases in SOD and reduced GSH levels.
Significantly reduced DSS-induced increases in colon tissue levels of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, and IL-18, and reduced IL-4 levels.
Significantly reversed DSS-induced increases in MPO activity, NF-κB DNA binding activity, caspase-1 activity, and active caspase-3 levels.
Significantly reduced DSS-induced increases in NLRP3 mRNA expression, NLRP3 protein levels, and gasdermin D N-terminal fragment (NGSDMD) levels.
Significantly increased BECN1 levels and decreased p62 levels compared to DSS-only rats, indicating enhanced autophagy.
Significantly increased colon tissue levels of tight junction proteins ZO-1, OCLN, and CLDN5 compared to DSS-only rats.
Significantly reversed DSS-induced changes in gut microbiome composition: reduced relative abundance of Fusobacterium spp., Clostridium spp., and increased relative abundance of Bifidobacterium spp. and Lactobacillus spp.
-
Animal Model:Sprague Dawley rats (male, 7 weeks old, 180-200 g)[1]
-
Dosage:4% w/w
-
Administration:p.o.; 24 days
-
Result:Increased plasma β-hydroxybutyrate levels, achieving nutritional ketosis.
Showed normal colonic mucosal architecture with regular rounded mucus-secreting glands and intact goblet cells, matching untreated normal rats.
-
Animal Model:C57BL/6J mice (male, 72 weeks of age, naturally aged to 83 weeks)[2]
-
Dosage:25% of dietary kcals
-
Administration:dietary; ad libitum; 9 weeks
-
Result:Showed no within-group change in body weight over time.
Prevented within-group increase in fat mass over time.
Increased expression of 6 skeletal muscle genes and decreased expression of 23 skeletal muscle genes.
Reduced fatty acyl chains in triacylglycerol in skeletal muscle.
Increased levels of 11 skeletal muscle proteins and decreased levels of 33 skeletal muscle proteins compared to controls.
-
Animal Model:C57BL/6 mice (male, 20 g)[3]
-
Dosage:2.5; 5.0; 10.0 g/kg
-
Administration:p.o.; single dose (20 minutes before hyperbaric oxygen exposure)
-
Result:Prolonged CNS oxygen toxicity seizure latency in a dose-dependent manner.
Increased mean seizure latency.
Significantly reduced hyperbaric oxygen-induced increases in brain malondialdehyde content.
Substantially alleviated hyperbaric oxygen-induced lung damage including congestion, inflammatory cell infiltration, and structural distortion, with only mild pulmonary vasodilation observed in treated groups.
Showed no effect on lung malondialdehyde content, as hyperbaric oxygen exposure did not affect this parameter.
-
Animal Model:Wistar rats (male, 250 g)[4]
-
Dosage:4 g/kg
-
Administration:i.g.; single dose
-
Result:Increased urethane-corrected PTZ seizure threshold.
Raised blood βHB levels.
Confirmed a significant treatment effect on PTZ threshold.
-
Animal Model:C57BL/6J mice (male, 5 weeks of age at study start, HFD-induced obesity)[5]
-
Dosage:30% of dietary energy
-
Administration:p.o.; 12 weeks
-
Result:Reduced final body weight.
Reduced final fat mass.
Lowered mean energy intake.
Increased adjusted resting energy expenditure (REE) and total energy expenditure (TEE) significantly compared to pair-fed controls.
Increased adjusted dark cycle REE and TEE compared to both continuous HFD and pair-fed controls.
Elevated circulating β-hydroxybutyrate concentration to 0.51 mM, higher than continuous HFD and pair-fed controls.
Increased mRNA expression of uncoupling protein-1, deiodinase-2, and peroxisome proliferator-activated receptor γ coactivator-1α in interscapular brown adipose tissue (BAT) compared to pair-fed controls.
Increased UCP1 protein expression in BAT compared to pair-fed controls.
Reduced hepatic triglyceride levels.
Lowered fasting serum insulin.
Decreased glucose tolerance test incremental area under the curve (AUCI) and insulin tolerance test AUCI compared to continuous HFD controls, similar to pair-fed controls.
Chemical Information
-
CAS No. 58213-75-5
-
Appearance Liquid
-
Molecular Weight 258.27
-
Formula C12H18O6
-
SMILES
O=C(CC(C)=O)OCCC(C)OC(CC(C)=O)=O
-
Synonyms
R,S-1,3-Butanediol acetoacetate diester
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (387.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (19.36 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (19.36 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
[1]. Saber S, Alamri MMS, Alfaifi J, et al.. (R,R)-BD-AcAc2 Mitigates Chronic Colitis in Rats: A Promising Multi-Pronged Approach Modulating Inflammasome Activity, Autophagy, and Pyroptosis. Pharmaceuticals (Basel, Switzerland). 2023 Jul 03;16(7):953. [Content Brief]
[2]. Roberts BM, et al. Effects of an exogenous ketone ester using multi-omics in skeletal muscle of aging C57BL/6J male mice. Front Nutr. 2022 Nov 15;9:1041026. [Content Brief]
[3]. Yi H, Yu S, Zhang Y, et al.. Preventive effects of ketone ester BD-AcAc on central nervous system oxygen toxicity and concomitant acute lung injury. Diving and hyperbaric medicine. 2018 Dec 24;48(4):235-240. [Content Brief]
[4]. Viggiano A, Pilla R, Arnold P, et al.. Anticonvulsant properties of an oral ketone ester in a pentylenetetrazole-model of seizure. Brain research. 2015 Aug 27;1618:50-4. [Content Brief]
[5]. Davis RAH, Deemer SE, Bergeron JM, et al.. Dietary R, S-1,3-butanediol diacetoacetate reduces body weight and adiposity in obese mice fed a high-fat diet. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019 Feb;33(2):2409-2421. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8719 mL | 19.3596 mL | 38.7192 mL | 96.7979 mL |
| 5 mM | 0.7744 mL | 3.8719 mL | 7.7438 mL | 19.3596 mL | |
| 10 mM | 0.3872 mL | 1.9360 mL | 3.8719 mL | 9.6798 mL | |
| 15 mM | 0.2581 mL | 1.2906 mL | 2.5813 mL | 6.4532 mL | |
| 20 mM | 0.1936 mL | 0.9680 mL | 1.9360 mL | 4.8399 mL | |
| 25 mM | 0.1549 mL | 0.7744 mL | 1.5488 mL | 3.8719 mL | |
| 30 mM | 0.1291 mL | 0.6453 mL | 1.2906 mL | 3.2266 mL | |
| 40 mM | 0.0968 mL | 0.4840 mL | 0.9680 mL | 2.4199 mL | |
| 50 mM | 0.0774 mL | 0.3872 mL | 0.7744 mL | 1.9360 mL | |
| 60 mM | 0.0645 mL | 0.3227 mL | 0.6453 mL | 1.6133 mL | |
| 80 mM | 0.0484 mL | 0.2420 mL | 0.4840 mL | 1.2100 mL | |
| 100 mM | 0.0387 mL | 0.1936 mL | 0.3872 mL | 0.9680 mL |
BD-AcAc2 Related Classifications
HY-159007 Related Classifications
Powered by Bioz
- BD-AcAc2
- 58213-75-5
- R,S-1,3-Butanediol acetoacetate diester
- Pyroptosis
- NF-κB
- NOD-like Receptor (NLR)
- Caspase
- Apoptosis
- Autophagy
- Reactive Oxygen Species (ROS)
- Oxidative Phosphorylation
- Interleukin Related
- NLRP3 inflammasome
- apoptosis
- gut barrier function
- autophagy
- skeletal muscle regeneration
- pyroptosis
- NFκB
- caspase-1
- caspase-3
- Sprague Dawley rats
- Inhibitor
- inhibitor
- inhibit